Discovery of a Novel 5-HT<sub>3</sub> Antagonist/5-HT<sub>1A</sub> Agonist 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3<i>H</i>)-one (TZB-30878) as an Orally Bioavailable Agent for Irritable Bowel Syndrome
作者:Akira Asagarasu、Teruaki Matsui、Hiroyuki Hayashi、Satoru Tamaoki、Yukinao Yamauchi、Kouichi Minato、Michitaka Sato
DOI:10.1021/jm1002292
日期:2010.11.11
We have prepared a series of quinazolinone derivatives linked with piperazinylquinoline for the treatment of irritable bowel syndrome (IBS). Using pharmacophore analysis, we designed and synthesized compounds which bind to both serotonin receptor subtype 1A (5-HT1A) and subtype 3 (5-HT3). Quinazolinone derivatives with a sulfur atom in the linker showed high affinity in in vitro assays, but low in vivo activity. Focusing on the linker to improve the pharmacokinetic profile, the sulfur atom in the linker was replaced with a methylene group. Further optimization led to the discovery of compound 17m (TZB-30878) (J. Pharmacol. Exp. Ther. 2007, 322, 1315-1323, Patent WO2005082887 (A1), 2005), a novel 5-HT1A agonist/5-HT3 antagonist in the 3-aminoquinazolinone series. In in vivo functional assays, 17m dose dependently inhibited the Bezold-Jarisch reflex and induced 5-HT1A-mediated behaviors, and in an IBS animal model, 17m significantly inhibited stress-induced defecation. Pretreatment by WAY-100635 (5-HT1A antagonist) significantly attenuated but did not abolish the inhibitory effects of 17m. These results suggested that 17m exerted inhibitory effects via both 5-HT1A agonistic and 5-HT3 antagonistic activities and that 17m would be useful as a therapeutic agent for IBS.
Structural Basis for Highly Selective Class II Alpha Phosphoinositide-3-Kinase Inhibition
作者:Murat Kücükdisli、Hassen Bel-Abed、Davide Cirillo、Wen-Ting Lo、Nina-Louisa Efrém、André Horatscheck、Liudmila Perepelittchenko、Polina Prokofeva、Theresa A. L. Ehret、Silke Radetzki、Martin Neuenschwander、Edgar Specker、Guillaume Médard、Susanne Müller、Stephanie Wilhelm、Bernhard Kuster、Jens Peter von Kries、Volker Haucke、Marc Nazaré
DOI:10.1021/acs.jmedchem.3c01319
日期:2023.10.26
NOVEL MOLECULES FOR REGULATING CELL DEATH
申请人:Nunnari Jodi
公开号:US20080287473A1
公开(公告)日:2008-11-20
The present invention provides compounds capable of regulating apoptosis, e.g., via regulating mitochondrial fission or fusion. The present invention also provides methods of screening for compounds capable of regulating apoptosis and methods of treating conditions association with apoptosis.
US8450333B2
申请人:——
公开号:US8450333B2
公开(公告)日:2013-05-28
[EN] COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS D'ASIC ET UTILISATIONS DE CEUX-CI
申请人:MERCK PATENT GMBH
公开号:WO2017045750A1
公开(公告)日:2017-03-23
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as ASIC inhibitors.